The need to compare rilonacept against active treatment for prevention of gout flares: Comment on the article by Schumacher et al

Arthritis and Rheumatism

Volumn 64, Issue 7, 2012, Pages 2415-2416

  Abeles, Aryeh M ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; PLACEBO; RILONACEPT;

GOUT; HUMAN; LETTER; PRIORITY JOURNAL;

ALLOPURINOL; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; RECOMBINANT FUSION PROTEINS;

EID: 84863198123     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34476     Document Type: Letter

References (3)

1. Schumacher HR Jr, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, et al, on behalf of the 0619 Study Group. Rilonacept (interleukin-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2012;64:876-84.
2. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429-32. (Pubitemid 39610535)
3. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1006-12. (Pubitemid 44133261)